Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/33666
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Loo, Sun | - |
dc.contributor.author | Roberts, Andrew W | - |
dc.contributor.author | Anstee, Natasha S | - |
dc.contributor.author | Kennedy, Glen A | - |
dc.contributor.author | He, Simon Zhao-Xiong | - |
dc.contributor.author | Schwarer, Anthony P | - |
dc.contributor.author | Enjeti, Anoop Kumar | - |
dc.contributor.author | D'Rozario, James | - |
dc.contributor.author | Marlton, Paula | - |
dc.contributor.author | Bilmon, Ian | - |
dc.contributor.author | Taper, John M | - |
dc.contributor.author | Cull, Gavin | - |
dc.contributor.author | Tiley, Campbell | - |
dc.contributor.author | Verner, Emma | - |
dc.contributor.author | Hahn, Uwe | - |
dc.contributor.author | Hiwase, Devendra K | - |
dc.contributor.author | Iland, Harry J | - |
dc.contributor.author | Murphy, Nicholas Edward | - |
dc.contributor.author | Ramanathan, Sundra | - |
dc.contributor.author | Reynolds, John | - |
dc.contributor.author | Ong, Doen Ming | - |
dc.contributor.author | Tiong, Ing Soo | - |
dc.contributor.author | Wall, Meaghan | - |
dc.contributor.author | Murray, Michael | - |
dc.contributor.author | Rawling, Tristan | - |
dc.contributor.author | Leadbetter, Joanna | - |
dc.contributor.author | Rowley, Leesa | - |
dc.contributor.author | Latimer, Maya | - |
dc.contributor.author | Yuen, Sam L S | - |
dc.contributor.author | Ting, Stephen B | - |
dc.contributor.author | Fong, Chun Yew | - |
dc.contributor.author | Morris, Kirk Lachlan | - |
dc.contributor.author | Bajel, Ashish | - |
dc.contributor.author | Seymour, John F | - |
dc.contributor.author | Levis, Mark J | - |
dc.contributor.author | Wei, Andrew H | - |
dc.date | 2023 | - |
dc.date.accessioned | 2023-09-06T07:03:31Z | - |
dc.date.available | 2023-09-06T07:03:31Z | - |
dc.date.issued | 2023-12-07 | - |
dc.identifier.citation | Blood 2023-12-07; 142(23) | en_US |
dc.identifier.issn | 1528-0020 | - |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/33666 | - |
dc.description.abstract | Sorafenib maintenance improves outcome after hematopoietic cell transplant (HCT) for patients with FLT3-ITD acute myeloid leukemia (AML). Although promising outcomes have been reported for sorafenib plus intensive chemotherapy, randomized data are limited. This placebo-controlled, phase 2 study (ACTRN12611001112954) randomized 102 patients 18-65 years (2:1) to sorafenib vs placebo (days 4-10) combined with intensive induction; idarubicin 12mg/m2 days 1-3 plus cytarabine 1.5g/m2 twice daily on days 1,3,5,7 (18-55 years) or 100mg/m2 days 1-7 (56-65 years), consolidation therapy, followed by maintenance treatment for 12 months (post-HCT excluded) in newly diagnosed FLT3-ITD AML. Four patients were excluded from modified intention-to-treat final analysis (3 not dosed and 1 later found to be FLT3-ITD negative). Rates of complete remission (CR)/CR with incomplete hematologic recovery (CR/CRi) were high in both arms (sorafenib 78%/9%, placebo 70%/24%). With 49.1 months median follow-up, the primary endpoint of event-free survival (EFS) was not improved by sorafenib (2-year EFS 47.9% vs 45.4%)(hazard ratio [HR] 0.87;95% confidence interval [CI] 0.51-1.51, p=0.61). Two-year overall survival (OS) was 67% in the sorafenib arm and 58% in the placebo arm (HR 0.76; 95% CI 0.42-1.39). For patients transplanted in first remission, 2-year OS was 84% and 67% in the sorafenib and placebo arms, respectively (HR 0.45;95% CI 0.18-1.12, p=0.08). In exploratory analyses, FLT3-ITD measurable residual disease negative status (<0.001%) post-induction was associated with improved 2-year OS (83% vs 60%) (HR 0.4;95% CI 0.17-0.93, p=0.028). In conclusion, routine use of pre-transplant sorafenib plus chemotherapy in unselected patients with FLT3-ITD AML is not supported by this study. | en_US |
dc.language.iso | eng | - |
dc.title | Sorafenib plus intensive chemotherapy in newly diagnosed FLT3-ITD AML:a randomized, placebo-controlled study by the ALLG. | en_US |
dc.type | Journal Article | en_US |
dc.identifier.journaltitle | Blood | en_US |
dc.identifier.affiliation | Peter MacCallum Cancer Centre and Walter and Eliza Hall Institute of Medical Research, 3052, Australia. | en_US |
dc.identifier.affiliation | Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Australia. | en_US |
dc.identifier.affiliation | Walter and Eliza Hall Institute of Medical Research, Parkville, Australia. | en_US |
dc.identifier.affiliation | Royal Brisbane and Women's Hospital, BRISBANE, Australia. | en_US |
dc.identifier.affiliation | Austin Health | en_US |
dc.identifier.affiliation | Box Hill Hospital, Melbourne, Australia. | en_US |
dc.identifier.affiliation | Calvary Mater Newcastle Hospital, Australia. | en_US |
dc.identifier.affiliation | Canberra Hospital, Garran, Australia. | en_US |
dc.identifier.affiliation | Princess Alexandra Hospital, Brisbane, Australia. | en_US |
dc.identifier.affiliation | Westmead Hospital, Westmead, Australia. | en_US |
dc.identifier.affiliation | Nepean Cancer Centre. Nepean Public Hospital, Penrith, Australia. | en_US |
dc.identifier.affiliation | Sir Charles Gairdiner Hospital, Nedlands, Australia. | en_US |
dc.identifier.affiliation | Gosford Hospital. | en_US |
dc.identifier.affiliation | Concord Repatriation General Hospital, Concord, Australia. | en_US |
dc.identifier.affiliation | Royal Adelaide and Queen Elizabeth Hospital, Adelaide, Australia. | en_US |
dc.identifier.affiliation | Royal Adelaide Hospital, Central Adelaide Local Health Network, Adelaide, Australia. | en_US |
dc.identifier.affiliation | Royal Prince Alfred Hospital, Camperdown, Australia. | en_US |
dc.identifier.affiliation | Royal Hobart Hospital, Hobart, Australia. | en_US |
dc.identifier.affiliation | St George Hospital, Kogarah, Australia. | en_US |
dc.identifier.affiliation | Monash University, Melbourne, VIC, Australia. | en_US |
dc.identifier.affiliation | The Alfred Hospital and Monash University, Melbourne, Australia. | en_US |
dc.identifier.affiliation | Peter MacCallum Cancer Centre, Melbourne, Australia. | en_US |
dc.identifier.affiliation | Murdoch Childrens Research Institute, Parkville, Australia. | en_US |
dc.identifier.affiliation | Sydney Pharmacy School, Sydney, Australia. | en_US |
dc.identifier.affiliation | University of Technology Sydney, Sydney, Australia. | en_US |
dc.identifier.affiliation | WriteSource Medical Pty Ltd, Sydney, Australia. | en_US |
dc.identifier.affiliation | Australasian Leukaemia & Lymphoma Group, Richmond, Australia. | en_US |
dc.identifier.affiliation | Canberra Hospital, Canberra, Australia. | en_US |
dc.identifier.affiliation | Calvary Mater Newcastle, Waratah, Australia. | en_US |
dc.identifier.affiliation | Royal Brisbane and Womens Hospital, Herston, Australia. | en_US |
dc.identifier.affiliation | Royal Melbourne Hospital, Parkville, Australia. | en_US |
dc.identifier.affiliation | Department of Hematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia. | en_US |
dc.identifier.affiliation | Johns Hopkins University, Baltimore, Maryland, United States. | en_US |
dc.identifier.affiliation | Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia. | en_US |
dc.identifier.doi | 10.1182/blood.2023020301 | en_US |
dc.type.content | Text | en_US |
dc.identifier.orcid | 0000-0001-6294-2691 | en_US |
dc.identifier.orcid | 0000-0002-7341-5720 | en_US |
dc.identifier.orcid | 0000-0003-2093-1403 | en_US |
dc.identifier.orcid | 0000-0002-9787-5908 | en_US |
dc.identifier.orcid | 0000-0002-8825-8625 | en_US |
dc.identifier.orcid | 0000-0001-7417-4343 | en_US |
dc.identifier.orcid | 0000-0002-6624-6586 | en_US |
dc.identifier.orcid | 0000-0001-7755-8326 | en_US |
dc.identifier.orcid | 0000-0001-5773-103X | en_US |
dc.identifier.orcid | 0000-0003-2188-6835 | en_US |
dc.identifier.orcid | 0000-0003-0473-6982 | en_US |
dc.identifier.orcid | 0000-0002-7514-3298 | en_US |
dc.identifier.pubmedid | 37647654 | - |
item.grantfulltext | none | - |
item.openairetype | Journal Article | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | Clinical Haematology | - |
crisitem.author.dept | Clinical Haematology | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.